The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study.
 
Laura Ann Huppert
No Relationships to Disclose
 
Elene Tsopurashvili
No Relationships to Disclose
 
Sai Sahitha Somepalle
No Relationships to Disclose
 
Amy Jo Chien
Honoraria - bioTheranostics; sanofi
Consulting or Advisory Role - Novartis; SeaGen
Research Funding - Amgen (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Melanie Majure
No Relationships to Disclose
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck
 
Ronald Balassanian
Stock and Other Ownership Interests - Cerus
Consulting or Advisory Role - Genentech
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Speakers' Bureau - AstraZeneca (I); Genentech (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); Novartis (Inst); OBI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline